Antivenom therapy in the Americas

Area of Science:

• Toxicology
• Immunology
• Pharmacology

Background:

• Envenomations represent a significant cause of injury across the Americas.
• Supportive care is standard, but specific antivenom therapy offers improved outcomes by neutralizing venom.
• Antivenoms are derived from hyperimmune animal sera containing antibodies against venom components.

Purpose of the Study:

• To describe the role and production of antivenoms for treating envenomations in the Americas.
• To outline the types of envenomations treated with antivenoms.
• To discuss the potential adverse effects associated with antivenom administration.

Main Methods:

• Antivenoms are produced by immunizing animals with venom, collecting serum, and processing it to concentrate antibodies.
• Processing techniques include precipitation, chromatography, and immunoglobulin cleavage to form Fab or F(ab)2 fragments.
• Antivenoms are specifically manufactured for crotalid and Micrurus snakebites, Latrodectus and Loxosceles spider bites, and Centruroides and Tityus scorpion stings.

Main Results:

• Antibodies in antivenom bind to and inactivate venom toxins, halting or reversing toxic effects.
• Processed antivenoms enhance antibody levels and reduce inactive proteins to minimize allergic reactions.
• Indications, administration, and adverse reaction profiles vary significantly among different antivenoms.

Conclusions:

• Antivenom therapy is a crucial intervention for envenomations in the Americas, significantly reducing morbidity.
• Allergic reactions, including potentially life-threatening anaphylaxis and serum sickness, are primary concerns.
• Pre-treatment preparedness for anaphylaxis is essential before administering antivenom therapy.